c-1a

Benazoline oxalate salt is a pharmacological active compound that inhibits casein kinase Iε (CKIε) or CKIδ phosphorylation of the PER2 protein.

C1A is an inhibitor of HDAC6 which modulates downstream autophagy substrates and leads to growth inhibition of a diverse set of cancer cell lines.

(-)-Indolactam V, a potent PKC activator, exhibits binding affinities (Kis) of 3.36 nM and 1.03 μM for η-CRD2 and γ-CRD2, respectively, and dissociation constants (Kds) of 5.5 nM (η-C1B), 7.7 nM (ε-C1B), 8.3 nM (δ-C1B), 18.9 nM (β-C1A-long), 20.8 nM (α-C1A-long), 137 nM (β-C1B), 138 nM (γ-C1A), and 213 nM (γ-C1B), also demonstrating antitumor activity.

Gentamicin C1a, acting as the major component of the Gentamicin complex [1] [2], serves as the precursor to the semi-synthetic antibiotic Etimicin and exhibits antibacterial activity.

1-Deamino-1-hydroxygentamicin C1a (AntibioticSU-2) is an aminoglycoside antibiotic effective against both gram-positive and gram-negative bacteria.

4"-Demethylgentamicin C1a exhibits activity against both Gram-positive and Gram-negative bacteria.

Bumetanide (PF 1593) is a potent sulfamoylanthranilic acid derivative belonging to the class of loop diuretics. In the brain, bumetanide may prevent seizures in neonates by blocking the bumetanide-sensitive sodium-potassium-chloride cotransporter (NKCC1), thereby inhibiting chloride uptake thus, decreasing the internal chloride concentration in neurons and may block the excitatory effect of GABA in neonates.

Azosemide is a potent NKCC1 inhibitor (IC50s: 0.246 µM and 0.197 µM for hNKCC1A and NKCC1B).

Azide-PEG3-C1-Ala is a PEG-based linker for PROTACs, joining two essential ligands to form PROTAC molecules, and enabling selective protein degradation through the ubiquitin-proteasome system within cells.

Biotin-PEG2-C1-aldehyde is a polyethylene glycol (PEG)-based linker used in the synthesis of proteolysis targeting chimeras (PROTACs) [1].

Nutlin-C1-amido-PEG4-C2-N3 is a novel ligand-linker conjugate for the E3 ligase, incorporating the MDM2 ligand from Nutlin 3 and a 4-unit PEG linker. This compound is specifically designed for use in PROTAC technology.

Estrone-N-O-C1-amido (ERα ligand 1) is an estrogen ligand derivative of Estrone that specifically binds to estrogen receptor α (ERα). With a linker, it complexes with the cIAP1 ligand Bestatin, forming SNIPER[1].

Propargyl-O-C1-amido-PEG2-C2-NHS ester is a non-cleavable 2-unit PEG linker used in antibody-drug conjugation (ADC) to connect antibodies with drugs.

Propargyl-O-C1-amido-PEG4-C2-NHS ester is a non-cleavable 4-unit PEG linker used in antibody-drug conjugation (ADC) to link antibodies with drugs.

DBCO-PEG3-C1-acid serves as a linker for antibody-drug conjugates (ADCs), facilitating the strain-promoted azide-alkyne click reaction as a reaction handle.

Boc-NH-PEG15-C1-acid is a PEG class PROTAC linker utilized in the synthesis of PROTAC molecules.

SLC1A1/EAAT3-IN-1 (Compound 3e) is a selective EAAT3 inhibitor with an IC50 of 7.2 μM for hEAAT3, while its IC50 values for EAAT1, EAAT2, and EAAT4 are approximately 250 μM. It is utilized in research related to psychiatric disorders such as obsessive-compulsive disorder and schizophrenia.

ASIC1a antagonist-1 (Compound 5b) is an orthosteric non-competitive antagonist of the acid-sensing ion channel 1a (ASIC1a) with an IC50 of 27 nM at pH 6.7. It alters the pH dependency of ASIC1a activation and suppresses its maximum response. Additionally, ASIC1a antagonist-1 completely inhibits the induction of long-term potentiation (LTP) in the CA3-CA1 pathway. This compound is useful for research into brain diseases and pathologies.

Bromoacetamide-PEG3-C1-acid is a PEG-based PROTAC linker used in PROTAC synthesis.

Propargyl-O-C1-amido-PEG3-C2-NHS ester is a non-cleavable 3-unit polyethylene glycol (PEG) linker utilized in the chemical synthesis of antibody-drug conjugates (ADCs).

Dc1a, a toxin isolated from the desert bush spider Diguetia canities [1], potently facilitates the opening of the German cockroach Na v channel (BgNa v 1).

Soluble epoxide hydrolase (sEH) PROTAC 1a is a proteolysis-targeting chimera (PROTAC) comprising a cereblon ligand linked to the sEH inhibitor t-TUCB via a linker, promoting selective sEH degradation and inhibiting its hydrolase activity (IC50 = 0.8 nM) significantly more than its phosphatase activity (IC50 = >10,000 nM). This compound preferentially targets cytosolic sEH for lysosomal rather than proteasomal degradation. Furthermore, it mitigates thapsigargin-induced upregulation of phosphorylated inositol-requiring enzyme 1α (IRE1α) and X-box binding protein 1 (XBP1) splicing in HepG2 and 293T cells, thereby reducing endoplasmic reticulum stress.

Anti-ASIC1 Antibody is a human-derived antibody expressed in CHO cells, targeting ASIC1. It features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145.22 kDa. For an isotype control, refer to HumanIgG1kappa, Isotype Control.

Tat-ASIC1a (1-20) (mouse, rat) is a competitive ASIC1a transmembrane peptide with significant neuroprotective effects. It alleviates acidotoxic neuronal damage by targeting the ASIC1a-RIPK1 pathway and an auto-inhibition mechanism. This compound effectively safeguards the brain in ischemic stroke mouse models against damage from ischemia and is applicable in research on neurodegenerative diseases, such as Huntington's disease and Parkinson’s disease.